Immunotherapy success in prophylaxis cannot predict therapy: Prime-boost vaccination against the 5T4 oncofoetal antigen

Cancer Immunology, Immunotherapy

Volumn 56, Issue 2, 2007, Pages 165-180

  Ali, Sumia ^a   Mulryan, Kate ^a   Taher, Taher ^a   Stern, Peter L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Cancer vaccine; CD25 regulatory T cells; Heterologous prime boost; Oncofoetal antigens; T helper response

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN AD5T4; PROTEIN DCH5T4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TH1 CELLS; TH2 CELLS; TRANSFECTION; VACCINATION;

EID: 33751551485     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0179-x     Document Type: Article

References (58)

1. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311:750-752
2. Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13-27
3. Beck C, Schreiber H, Rowley D (2001) Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech 52:387-395
4. von Boehmer H (2005) Mechanisms of suppression by suppressor T cells. Nat Immunol 6:338-344
5. Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5:508-515
6. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274
7. Dermime S, Armstrong A, Hawkins RE, Stern PL (2002) Cancer vaccines and immunotherapy. Br Med Bull 62:149-162
8. Hole N, Stern PL (1988) A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 57:239-246
9. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61:89-95
10. Mulder WM, Stern PL, Stukart MJ, de Windt E, Butzelaar RM, Meijer S, Ader HJ, Claessen AM, Vermorken JB, Meijer CJ, Wagstaff J, Scheper RJ, Bloemena E (1997) Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 3:1923-1930
11. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka K, Matsumoto Y (2002) Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 22:1033-1038
12. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 69:899-902
13. Starzynska T, Rahi V, Stern PL (1992) The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 66:867-869
14. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley M, Roberts SA, Lawniczak M, Kolodziej B, Zyluk A, Stern PL (1998) 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol 10:479-484
15. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, Stern PL (1995) 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 5:269-274
16. Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM, Stern PL, Carroll MW (2002) Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 1:1129-1137
17. Smyth L, Elkord E , Taher TEI, Jiang h-R, Burt DJ, Clayton A, van Veelen PA, de Ru A, Ossendorp F, Melief CJM, Drijfhout JW, Dermime S, Hawkins RE, Stern PL (2006) CD8 T cell recognition of human 5T4 oncofoetal antigen Int J cancer (in press)
18. Hodge JW, McLaughlin JP, Kantor JA, Schlom J (1997) Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15:759-768
19. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP (1997) Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 89:1595-1601
20. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V (2002) Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168:4391-4398
21. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC (2003) Induction of CD8 + T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171:6774-6779
22. Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE (2002) Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 168:3983-3991
23. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP (1996) Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156:224-231
24. Dranoff G, Mulligan RC (1995) Gene transfer as cancer therapy. Adv Immunol 58:417-454
25. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322
26. Pardoll DM (2002) Tumor reactive T cells get a boost. Nat Biotechnol 20:1207-1208
27. Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183-1187
28. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R (2001) Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 97:1370-1377
29. Mendoza L, Bubenik J, Simova J, Jandlova T, Vonka V, Mikyskova R (2003) Prophylactic, therapeutic and antimetastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 23:243-247
30. Mendoza L, Bubenik J, Simova J, Korb J, Bieblova J, Vonka V, Indrova M, Mikyskova R, Jandlova T (2002) Tumour-inhibitory effects of dendritic cells administered at the site of HPV 16-induced neoplasms. Folia Biol (Praha) 48:114-119
31. Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723-2730
32. Winkelhake JL, Nicolson GL (1976) Determination of adhesive properties of variant metastatic melanoma cells to BALB/3T3 cells and their virus-transformed derivatives by a monolayer attachment assay. J Natl Cancer Inst 56:285-291
33. Myers KA, Rahi-Saund V, Davison MD, Young JA, Cheater AJ, Stern PL (1994) Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem 269:9319-9324
34. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML (1997) Construction of adenovirus vectors through Cre-lox recombination. J Virol 71:1842-1849
35. Li Y, Tew SR, Russell AM, Gonzalez KR, Hardingham TE, Hawkins RE (2004) Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng 10:575-584
36. Fairbairn ES (1993) Retroviral gene transfer into haemopoietic cells. In: Testa N, Molineux G (eds) Haemopoiesis: a practical approach. Oxford University Press, New York, pp 175-187
37. Shaw DM, Woods AM, Myers KA, Westwater C, Rahi-Saund V, Davies MJ, Renouf DV, Hounsell EF, Stern PL (2002) Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen. Biochem J 363:137-145
38. Zinkernagel RM (2000) Localization dose and time of antigens determine immune reactivity (discussion 257-344). Semin Immunol 12:163-171
39. Krebs P, Scandella E, Odermatt B, Ludewig B (2005) Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J Immunol 174:4559-4566
40. Okada N, Tsujino M, Hagiwara Y, Tada A, Tamura Y, Mori K, Saito T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A (2001) Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 84:1564-1570
41. Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Mondino A, Bellone M (2003) Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 63:3688-3694
42. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1:311-316
43. Reinis M (2004) Technology evaluation: TroVax, Oxford BioMedica. Curr Opin Mol Ther 6:436-442
44. Adamina M, Daetwiler S, Rosenthal R, Zajac P (2005) Clinical applications of recombinant virus-based cancer immunotherapy. Expert Opin Biol Ther 5:1211-1224
45. Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T (2005) Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol 2:108-113
46. Reichardt VL, Brossart P, Kanz L (2004) Dendritic cells in vaccination therapies of human malignant disease. Blood Rev 18:235-243
47. Salazar LG, Disis ML (2005) Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol 23:7397-7398
48. Cuenca A, Cheng F, Wang H, Brayer J, Horna PGuL, Bien H, Borrello IM, Levitsky HI, Sotomayor EM (2003) Extralymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 63:9007-9015
49. Melief CJ (2003) Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 33:2645-2654
50. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky (2001) H. I. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98:1070-1077
51. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200:771-782
52. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, Chen SJ, Varnavski AN, LeClair C, Raper SE, Wilson JM (2001) Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3:708-722
53. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, Tazelaar J, Wilson JM (2001) Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3:697-707
54. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo O, Moser M (2003) CD4 + CD25 + regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 198:259-266
55. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE (2005) CD4 + Tcells are able to promote tumor growth through inhibition of tumor-specific CD8 + T-cell responses in tumor-bearing hosts. Cancer Res 65:6984-6989
56. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, Gejyo F, Yoshizawa H (2005) Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175:5058-5066
57. Zhou G, Drake CG, Levitsky HI (2005) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood
58. Huang Y, Obholzer N, Fayad R, Qiao L (2005) Turning on/off tumor-specific CTL response during progressive tumor growth. J Immunol 175:3110-3116